These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20944800)

  • 41. Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.
    Ankerst DP; Gelfond J; Goros M; Herrera J; Strobl A; Thompson IM; Hernandez J; Leach RJ
    J Urol; 2016 Aug; 196(2):355-60. PubMed ID: 26979652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
    Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
    J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
    de la Taille A; Houlgatte A; Houdelette P; Berlizot P; Ramirez J; Ricordel I
    Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
    Thakur V; Singh PP; Talwar M; Mukherjee U
    Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The significance of early detection for prostate cancer in mass screening].
    Kato M; Tammbo M; Yoshimatsu T; Ohta M; Kinjyo M; Noda H; Watanabe K; Miyata A; Murata A; Miura I; Yoneda T; Yoshii M; Okegawa T; Kojima M; Sayama T; Nutahara K; Higashihara E
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):23-9. PubMed ID: 11235139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significance of serum free prostate specific antigen in the screening of prostate cancer.
    Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
    J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-Benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer.
    Murray NP; Reyes E; Orellana N; Tapía P
    Arch Esp Urol; 2013 Apr; 66(3):277-86. PubMed ID: 23648747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002.
    Saraiya M; Kottiri BJ; Leadbetter S; Blackman D; Thompson T; McKenna MT; Stallings FL
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2178-82. PubMed ID: 16172229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
    Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
    J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
    Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
    Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
    Pannek J; Rittenhouse HG; Chan DW; Epstein JI; Walsh PC; Partin AW
    J Urol; 1998 Apr; 159(4):1238-42. PubMed ID: 9507844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
    Haroun AA; Hadidy AS; Awwad ZM; Nimri CF; Mahafza WS; Tarawneh ES
    Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):291-7. PubMed ID: 21422628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
    Woodrum DL; Brawer MK; Partin AW; Catalona WJ; Southwick PC
    J Urol; 1998 Jan; 159(1):5-12. PubMed ID: 9400426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA.
    Morgan TO; McLeod DG; Leifer ES; Moul JW; Murphy GP
    Prostate Suppl; 1996; 7():58-63. PubMed ID: 8950365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
    Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
    Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.